(BTSG) BrightSpring Health - Ratings and Ratios
Pharmacy, Home, Rehabilitation, Medication
BTSG EPS (Earnings per Share)
BTSG Revenue
Description: BTSG BrightSpring Health
BrightSpring Health Services, Inc. is a leading provider of home and community-based healthcare services in the United States, operating through its two main segments: Pharmacy Solutions and Provider Services. The companys comprehensive platform delivers a range of pharmacy and provider services, including clinical and supportive care, to Medicare, Medicaid, and insured populations. With a focus on patient-centric care, BrightSpring offers infused, injectable, and oral medication services, as well as highly skilled clinical home health care and rehabilitation services, including physical, speech, and occupational therapy, and applied behavioral analysis.
As a healthcare services company, BrightSpring operates in a growing market driven by an aging population and increasing demand for home-based care. The companys services are designed to support patients with complex needs, and its platform is built to provide high-quality, cost-effective care. With its headquarters in Louisville, Kentucky, BrightSpring has established itself as a significant player in the healthcare services industry, with a history dating back to 1974.
Analyzing the technical data, we can see that the stock is currently trading at $22.24, below its 20-day SMA of $23.58, indicating a potential short-term downtrend. However, the stock is above its 50-day SMA of $20.42 and 200-day SMA of $18.29, suggesting a longer-term uptrend. The ATR of 1.17 (5.25%) indicates moderate volatility. Considering the support and resistance levels, the stock has a strong support base between $17.0 and $18.7, and resistance around $23.0 and $23.9.
From a fundamental perspective, BrightSprings market capitalization is approximately $4.2 billion, with a P/E ratio of 89.30 and a forward P/E of 41.49. The companys return on equity is 3.50%, indicating room for improvement in terms of profitability. Given the current valuation and growth prospects, we can forecast that BrightSprings stock may experience a moderate increase in the short term, potentially reaching $25.00, driven by its growing revenue and expanding services. However, the high P/E ratio and volatility may pose risks, and investors should closely monitor the companys financial performance and industry trends.
Based on the analysis, our forecast is that BrightSpring Health Services, Inc. Common Stock (BTSG) will experience a gradual increase in value over the next quarter, driven by its strong market position, growing demand for home-based care, and expanding services. We predict that the stock will reach $24.50, representing a 10% increase from its current price. However, investors should be cautious of the potential risks and monitor the companys performance closely.
Additional Sources for BTSG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
BTSG Stock Overview
Market Cap in USD | 3,868m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2024-01-26 |
BTSG Stock Ratings
Growth Rating | 52.1 |
Fundamental | 6.98 |
Dividend Rating | 0.0 |
Rel. Strength | 88.2 |
Analysts | 4.67 of 5 |
Fair Price Momentum | 21.88 USD |
Fair Price DCF | 13.02 USD |
BTSG Dividends
Currently no dividends paidBTSG Growth Ratios
Growth Correlation 3m | 10.1% |
Growth Correlation 12m | 78.7% |
Growth Correlation 5y | 91.2% |
CAGR 5y | 49.73% |
CAGR/Max DD 5y | 1.40 |
Sharpe Ratio 12m | 0.78 |
Alpha | 57.45 |
Beta | 0.914 |
Volatility | 41.16% |
Current Volume | 1108k |
Average Volume 20d | 1710.1k |
Stop Loss | 19.2 (-3.8%) |
As of July 19, 2025, the stock is trading at USD 19.95 with a total of 1,107,985 shares traded.
Over the past week, the price has changed by -1.80%, over one month by -10.88%, over three months by +27.69% and over the past year by +71.50%.
Neither. Based on ValueRay´s Fundamental Analyses, BrightSpring Health is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 6.98 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BTSG is around 21.88 USD . This means that BTSG is currently overvalued and has a potential downside of 9.67%.
BrightSpring Health has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy BTSG.
- Strong Buy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, BTSG BrightSpring Health will be worth about 24.3 in July 2026. The stock is currently trading at 19.95. This means that the stock has a potential upside of +21.9%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 28.1 | 40.9% |
Analysts Target Price | 27.3 | 36.8% |
ValueRay Target Price | 24.3 | 21.9% |